sinobiopharmaceutical
香港, 2024年3月29日- (亚太商讯) - 中国领先的创新研发驱动型医药集团—中国生物制药有限...
ACN Newswire (简体中文)
創新產品 繼續豐收 收入達人民幣262.0億元經調整非《香港財務報告準則》歸母淨利潤達人民幣25.9億元 香港, 2024年3月29日 - (亞太商訊) - 中國領先的創新研發驅動型醫藥集團—中國生物製藥有限公司(「中國生物製藥」或「公司」,連同附屬公司統稱「集團」)(股票編號:1177)公布截至2023年12月31日止12個月之經審核財務業績。 年內,集團錄得收入約262.0億元(人民幣,下同),按年增長約0.7%。歸屬於母公司持有者應佔盈利約23.3億元。基於歸屬於母公司持有者應佔盈利計算之每股盈利約12.59分,按年減少約7.8%,該減少主要由於一聯營公司財務表現低於去年所致。扣除已終止經營業務之歸屬於母公司持有者應佔盈利、應佔聯營公司及一家合營公司盈利及虧損(扣除相關稅項及非控制權益)、若干資產及負債之公允價值變動及一次性調整之減值(扣除相關稅項及非控制權益),流動權益投資之公允價值(利潤)╱ 虧損、股權激勵費用(扣除相關非控制權益)、註銷部份可轉換債券之虧損、可轉換債券嵌入衍生部份之公允價值變動收益、可轉換債券債務部份之利息費用、匯兌收益及與外匯遠期合約有關的衍生金融工具之公允價值虧損之影響後,經調整非《香港財務報告準則》歸母淨利潤約25.9億元,按年增長約1.5%。集團流動資金保持充裕,資金儲備總額約211.3億元(計入流動資產之現金及銀行結餘約94.5億元、計入非流動...
ACN Newswire (正體中文)
Innovative Products Continued to Deliver and Perform ExcellentlyRevenue Recorded RMB26.20 BillionAdjusted non-HKFRS Profit Attributable to the Owners of the Parent Recorded RMB2.59 Billion HONG KONG, Mar 29, 2024 - (ACN Newswire) - Sino Biopharmaceutical Limited (Sino Biopharm or the Company, together with its subsidiaries, the Group) (HKG:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited financial results for the year ended 31 December 2023. During the year, the Group recorded revenue of approximately RMB26.20 billion, an increase of approxim...
ACN Newswire
Steadily Advances Innovation and R&DRevenue Climbs to RMB15.28 BillionAdjusted Non-HKFRS Profit Attributable to the Owners of the Parent up 1.2%Strong Recovery in Q2 Revenue up 30.0%Adjusted Non-HKFRS Profit Attributable to the Owners of the Parent up 20.7% HONG KONG, Aug 25, 2023 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2023 (the "Period"). ...
ACN Newswire
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら